Clinical Trial Update: Cost-effectiveness of RFA vs. PEI for Early-stage HCC [NA]

View source ↗

Summary

A completed trial compares the cost-effectiveness of radiofrequency ablation versus percutaneous ethanol injection for early-stage hepatocellular carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Percutaneous ethanol injection (PEI) (percutaneous ethanol injection)
• Radiofrequency ablation (RFA) (radiofrequency ablation)

Snippet

Sponsor: Hospital Israelita Albert Einstein | Conditions: Cost Effectiveness, Exposure to Radiofrequency | NA | Status: COMPLETED